Thelin sitaxsentan: Phase II/III data

Results from an extension of the Phase IIb/III STRIDE-1 trial in 170 patients, 53% and 44% of those given 100 mg and 300 mg once-daily sitaxsentan improved at least 1 NYHA functional class after a mea...